The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 72; no. 6; pp. 986 - 991
Main Authors Helliwell, Philip S, FitzGerald, Oliver, Fransen, Jaap, Gladman, Dafna D, Kreuger, Gerald G, Callis-Duffin, Kristina, McHugh, Neil, Mease, Philip J, Strand, Vibeke, Waxman, Robin, Azevedo, Valderilio Feijo, Beltran Ostos, Adriana, Carneiro, Sueli, Cauli, Alberto, Espinoza, Luis R, Flynn, John A, Hassan, Nada, Healy, Paul, Kerzberg, Eduardo Mario, Lee, Yun Jong, Lubrano, Ennio, Marchesoni, Antonio, Marzo-Ortega, Helena, Porru, Giovanni, Moreta, Elvia G, Nash, Peter, Raffayova, Helena, Ranza, Roberto, Raychaudhuri, Siba P, Roussou, Euthalia, Scarpa, Raphael, Song, Yeong Wook, Soriano, Enrique R, Tak, Paul P, Ujfalussy, Ilona, de Vlam, Kurt, Walsh, Jessica A
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2013
Elsevier Limited
Subjects
Adult
Arthritis
Arthritis, Psoriatic - diagnosis
Bowel disease
Colleges & universities
Dermatology
Female
Humans
Linear Models
Male
Middle Aged
Psoriasis
Quality
Rheumatic diseases
Rheumatology
ROC Curve
Severity of Illness Index
Skin
Teaching hospitals
United Kingdom > UK
Online AccessGet full text
ISSN0003-4967
1468-2060
1468-2060
DOI10.1136/annrheumdis-2012-201341

Cover

Abstract Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.
AbstractList To develop new composite disease activity indices for psoriatic arthritis (PsA).OBJECTIVETo develop new composite disease activity indices for psoriatic arthritis (PsA).Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28).METHODSData from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28).161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index>10) both nonparametric and AUC curve statistics were nonsignificant for all measures.RESULTS161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index>10) both nonparametric and AUC curve statistics were nonsignificant for all measures.Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.CONCLUSIONSTwo new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.
To develop new composite disease activity indices for psoriatic arthritis (PsA). Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression (psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease (psoriasis area and severity index>10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.
Author Kerzberg, Eduardo Mario
Helliwell, Philip S
Healy, Paul
Soriano, Enrique R
Moreta, Elvia G
Espinoza, Luis R
FitzGerald, Oliver
Strand, Vibeke
Cauli, Alberto
Ranza, Roberto
Scarpa, Raphael
Tak, Paul P
Lubrano, Ennio
Raffayova, Helena
Roussou, Euthalia
Marchesoni, Antonio
Ujfalussy, Ilona
McHugh, Neil
Porru, Giovanni
Gladman, Dafna D
Kreuger, Gerald G
Waxman, Robin
Marzo-Ortega, Helena
Mease, Philip J
Walsh, Jessica A
Lee, Yun Jong
Nash, Peter
Flynn, John A
Callis-Duffin, Kristina
Beltran Ostos, Adriana
Azevedo, Valderilio Feijo
Song, Yeong Wook
de Vlam, Kurt
Raychaudhuri, Siba P
Hassan, Nada
Fransen, Jaap
Carneiro, Sueli
Author_xml – sequence: 1
  givenname: Philip S
  surname: Helliwell
  fullname: Helliwell, Philip S
  email: p.helliwell@leeds.ac.uk
  organization: Bradford Teaching Hospitals NHS Foundation Trust, UK
– sequence: 2
  givenname: Oliver
  surname: FitzGerald
  fullname: FitzGerald, Oliver
  email: p.helliwell@leeds.ac.uk
  organization: St Vincent's University Hospital and University College Dublin, Dublin, Ireland
– sequence: 3
  givenname: Jaap
  surname: Fransen
  fullname: Fransen, Jaap
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, The Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
– sequence: 4
  givenname: Dafna D
  surname: Gladman
  fullname: Gladman, Dafna D
  email: p.helliwell@leeds.ac.uk
  organization: Centre for Prognosis in the Rheumatic Diseases, University of Toronto, Toronto, Canada
– sequence: 5
  givenname: Gerald G
  surname: Kreuger
  fullname: Kreuger, Gerald G
  email: p.helliwell@leeds.ac.uk
  organization: Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
– sequence: 6
  givenname: Kristina
  surname: Callis-Duffin
  fullname: Callis-Duffin, Kristina
  email: p.helliwell@leeds.ac.uk
  organization: Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
– sequence: 7
  givenname: Neil
  surname: McHugh
  fullname: McHugh, Neil
  email: p.helliwell@leeds.ac.uk
  organization: Royal National Hospital for Rheumatic Diseases, Bath, UK
– sequence: 8
  givenname: Philip J
  surname: Mease
  fullname: Mease, Philip J
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, University of Washington, Seattle, Washington, USA
– sequence: 9
  givenname: Vibeke
  surname: Strand
  fullname: Strand, Vibeke
  email: p.helliwell@leeds.ac.uk
  organization: Division of Immunology and Rheumatology, Stanford University, Portola Valley, California, USA
– sequence: 10
  givenname: Robin
  surname: Waxman
  fullname: Waxman, Robin
  email: p.helliwell@leeds.ac.uk
  organization: Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK
– sequence: 11
  givenname: Valderilio Feijo
  surname: Azevedo
  fullname: Azevedo, Valderilio Feijo
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, Federal University of Paraná, Rebouças – Paraná, Brasil
– sequence: 12
  givenname: Adriana
  surname: Beltran Ostos
  fullname: Beltran Ostos, Adriana
  email: p.helliwell@leeds.ac.uk
  organization: Clinical Rheumatology, Clinical Rheumatology Hospital de la Policia, Bogota, Colombia
– sequence: 13
  givenname: Sueli
  surname: Carneiro
  fullname: Carneiro, Sueli
  email: p.helliwell@leeds.ac.uk
  organization: University Hospital HUCFF of Federal University of Rio de Janeiro, Rio de Janeiro, Brasil
– sequence: 14
  givenname: Alberto
  surname: Cauli
  fullname: Cauli, Alberto
  email: p.helliwell@leeds.ac.uk
  organization: Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy
– sequence: 15
  givenname: Luis R
  surname: Espinoza
  fullname: Espinoza, Luis R
  email: p.helliwell@leeds.ac.uk
  organization: Section of Rheumatology, LSU Health Sciences Center, New Orleans, Louisiana, USA
– sequence: 16
  givenname: John A
  surname: Flynn
  fullname: Flynn, John A
  email: p.helliwell@leeds.ac.uk
  organization: School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
– sequence: 17
  givenname: Nada
  surname: Hassan
  fullname: Hassan, Nada
  email: p.helliwell@leeds.ac.uk
  organization: Rheumatology Department, Southend University Hospital, Westcliff-on-sea, UK
– sequence: 18
  givenname: Paul
  surname: Healy
  fullname: Healy, Paul
  email: p.helliwell@leeds.ac.uk
  organization: Hutt Valley District Health Board, Lower Hutt, New Zealand
– sequence: 19
  givenname: Eduardo Mario
  surname: Kerzberg
  fullname: Kerzberg, Eduardo Mario
  email: p.helliwell@leeds.ac.uk
  organization: School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
– sequence: 20
  givenname: Yun Jong
  surname: Lee
  fullname: Lee, Yun Jong
  email: p.helliwell@leeds.ac.uk
  organization: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Korea
– sequence: 21
  givenname: Ennio
  surname: Lubrano
  fullname: Lubrano, Ennio
  email: p.helliwell@leeds.ac.uk
  organization: Department of Health Sciences, University of Molise, Campobasso, Italy
– sequence: 22
  givenname: Antonio
  surname: Marchesoni
  fullname: Marchesoni, Antonio
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, Istituto Ortopedico G. Pini, Milan, Italy
– sequence: 23
  givenname: Helena
  surname: Marzo-Ortega
  fullname: Marzo-Ortega, Helena
  email: p.helliwell@leeds.ac.uk
  organization: Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK
– sequence: 24
  givenname: Giovanni
  surname: Porru
  fullname: Porru, Giovanni
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, University of Cagliari, Cagliari, Italy
– sequence: 25
  givenname: Elvia G
  surname: Moreta
  fullname: Moreta, Elvia G
  email: p.helliwell@leeds.ac.uk
  organization: St Paul Rheumatology, Eagan, Minnesota, USA
– sequence: 26
  givenname: Peter
  surname: Nash
  fullname: Nash, Peter
  email: p.helliwell@leeds.ac.uk
  organization: Department of Medicine, University of Queensland, Maroochydore, Australia
– sequence: 27
  givenname: Helena
  surname: Raffayova
  fullname: Raffayova, Helena
  email: p.helliwell@leeds.ac.uk
  organization: National Institute of Rheumatic Diseases, Piešt'any, Slovakia
– sequence: 28
  givenname: Roberto
  surname: Ranza
  fullname: Ranza, Roberto
  email: p.helliwell@leeds.ac.uk
  organization: Rheumatology Unit, Universidade Federal de Uberlândia, Uberlândia, Brasil
– sequence: 29
  givenname: Siba P
  surname: Raychaudhuri
  fullname: Raychaudhuri, Siba P
  email: p.helliwell@leeds.ac.uk
  organization: Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Davis, California, USA
– sequence: 30
  givenname: Euthalia
  surname: Roussou
  fullname: Roussou, Euthalia
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, Barking Havering and Redbridge University Hospitals NHS Trust, London, UK
– sequence: 31
  givenname: Raphael
  surname: Scarpa
  fullname: Scarpa, Raphael
  email: p.helliwell@leeds.ac.uk
  organization: University Federico II, Naples, Italy
– sequence: 32
  givenname: Yeong Wook
  surname: Song
  fullname: Song, Yeong Wook
  email: p.helliwell@leeds.ac.uk
  organization: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
– sequence: 33
  givenname: Enrique R
  surname: Soriano
  fullname: Soriano, Enrique R
  email: p.helliwell@leeds.ac.uk
  organization: Rheumatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
– sequence: 34
  givenname: Paul P
  surname: Tak
  fullname: Tak, Paul P
  email: p.helliwell@leeds.ac.uk
  organization: Clinical Immunology and Rheumatology, F-, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
– sequence: 35
  givenname: Ilona
  surname: Ujfalussy
  fullname: Ujfalussy, Ilona
  email: p.helliwell@leeds.ac.uk
  organization: National Health Center, Military Hospital, Budapest, Hungary
– sequence: 36
  givenname: Kurt
  surname: de Vlam
  fullname: de Vlam, Kurt
  email: p.helliwell@leeds.ac.uk
  organization: Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium
– sequence: 37
  givenname: Jessica A
  surname: Walsh
  fullname: Walsh, Jessica A
  email: p.helliwell@leeds.ac.uk
  organization: Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22798567$$D View this record in MEDLINE/PubMed
BookMark eNqNkU9v1DAQxS1URLeFrwCWuJRDIHYc2zlwKKv-QRQQqCBulmNPtF6SOLWdqv329SotQr3AxfZIv-c3M-8A7Y1-BIRekfItIRV_p8cxbGAerIsFLQndHRUjT9CKMC5zxcs9tCrLsipYw8U-Oohxm8tSEvkM7VMqGllzsULz5QawhWvo_TTAmLDvsNGjdVYnwMYPk48uv7IR6AhYm-SuXbrFmcEB4uRHCwG7rDAQcecDnqIPTidnsA5pE1xyER-dfT9en-Ap-C2Y9OY5etrpPsKL-_sQ_Tg9uVyfFxdfzz6ujy-KllGaCg2NIJxXLetYV1lqiazzDLURsmWE11rKCowWQBtCadty23BKeCeYaLjtWHWIjpZ_s_HVDDGpwUUDfa9H8HNUpKpL2RDJqoy-foRu_RzG3J0iQgiZnUWTqZf31NwOYNUU3KDDrXpYaAbeL4AJPsYAnTIu5WX4MQXtekVKtQtQ_RWg2gWolgCzXjzSP1j8W1ksShcT3PyR6fBb5b5Erb78XKvP336dfzr9UCmaebrw7bD9b5M7nL7Dew
CODEN ARDIAO
CitedBy_id crossref_primary_10_1080_1744666X_2020_1685382
crossref_primary_10_1093_rheumatology_keab504
crossref_primary_10_1136_annrheumdis_2016_210724
crossref_primary_10_1007_s10067_014_2763_3
crossref_primary_10_1111_1756_185X_14310
crossref_primary_10_2340_actadv_v102_2225
crossref_primary_10_1177_2475530318774266
crossref_primary_10_1016_j_semarthrit_2018_02_002
crossref_primary_10_1586_1744666X_2016_1146133
crossref_primary_10_3899_jrheum_170449
crossref_primary_10_1016_j_reumae_2017_08_002
crossref_primary_10_1093_rheumatology_keac025
crossref_primary_10_1093_rheumatology_kez215
crossref_primary_10_1002_acr_24242
crossref_primary_10_1136_rmdopen_2022_002457
crossref_primary_10_1136_annrheumdis_2014_205267
crossref_primary_10_1111_1756_185X_14663
crossref_primary_10_1038_nrrheum_2018_15
crossref_primary_10_1093_rheumatology_keaa766
crossref_primary_10_2217_ijr_14_6
crossref_primary_10_3899_jrheum_150826
crossref_primary_10_1007_s00296_018_4153_7
crossref_primary_10_1136_annrheumdis_2016_211010
crossref_primary_10_1136_annrheumdis_2017_211998
crossref_primary_10_1186_s13063_020_4097_6
crossref_primary_10_1007_s11926_020_00958_9
crossref_primary_10_1136_annrheumdis_2020_219014
crossref_primary_10_1016_S1286_935X_21_45566_8
crossref_primary_10_1136_rmdopen_2021_001756
crossref_primary_10_1093_rheumatology_kez202
crossref_primary_10_1136_annrheumdis_2017_211996
crossref_primary_10_1016_j_berh_2023_101862
crossref_primary_10_1136_rmdopen_2023_003977
crossref_primary_10_1016_j_intimp_2024_113279
crossref_primary_10_46833_reumatologiasp_2022_21_2_26_35
crossref_primary_10_1002_acr2_11732
crossref_primary_10_1007_s00296_018_4201_3
crossref_primary_10_1007_s10067_020_05142_z
crossref_primary_10_1136_bmj_2024_081860
crossref_primary_10_1177_1203475418824565
crossref_primary_10_1007_s00296_022_05159_4
crossref_primary_10_1007_s40744_023_00588_4
crossref_primary_10_1186_s13063_019_4000_5
crossref_primary_10_1002_acr_22404
crossref_primary_10_3899_jrheum_150614
crossref_primary_10_1002_acr_22529
crossref_primary_10_1007_s00393_023_01326_5
crossref_primary_10_1093_rheumatology_keac375
crossref_primary_10_1093_rheumatology_kead455
crossref_primary_10_1002_acr_23176
crossref_primary_10_1002_acr_22401
crossref_primary_10_1186_s13075_020_2126_1
crossref_primary_10_1186_s12891_016_1102_z
crossref_primary_10_1007_s40744_024_00702_0
crossref_primary_10_1136_annrheumdis_2015_208337
crossref_primary_10_1007_s10067_017_3578_9
crossref_primary_10_1186_s13075_021_02680_y
crossref_primary_10_1093_rheumatology_keab272
crossref_primary_10_14412_1996_7012_2019_2_112_118
crossref_primary_10_1093_rheumatology_kead202
crossref_primary_10_1093_rheumatology_kex400
crossref_primary_10_1136_annrheumdis_2017_211613
crossref_primary_10_1136_annrheumdis_2017_211734
crossref_primary_10_26442_00403660_2023_05_202197
crossref_primary_10_1007_s10067_021_05774_9
crossref_primary_10_1038_nrrheum_2014_106
crossref_primary_10_1002_art_42519
crossref_primary_10_1016_S2665_9913_21_00349_0
crossref_primary_10_1016_j_semarthrit_2021_06_008
crossref_primary_10_1136_rmdopen_2022_002789
crossref_primary_10_3899_jrheum_150595
crossref_primary_10_1586_1744666X_2014_943663
crossref_primary_10_1586_14737167_2014_917970
crossref_primary_10_1111_1756_185X_14357
crossref_primary_10_1002_acr_23876
crossref_primary_10_1093_rheumatology_keaa298
crossref_primary_10_1080_09546634_2019_1605142
crossref_primary_10_1155_2014_528105
crossref_primary_10_1007_s40744_015_0020_0
crossref_primary_10_1093_rheumatology_kead679
crossref_primary_10_1016_j_berh_2018_08_004
crossref_primary_10_1002_acr_24046
crossref_primary_10_1007_s00296_019_04480_9
crossref_primary_10_1093_rheumatology_kez372
crossref_primary_10_1186_s13075_023_03125_4
crossref_primary_10_1093_rheumatology_kez254
crossref_primary_10_3899_jrheum_160973
crossref_primary_10_1136_annrheumdis_2020_216999
crossref_primary_10_1186_1471_2474_15_26
crossref_primary_10_1007_s12325_014_0142_8
crossref_primary_10_1016_S2665_9913_22_00028_5
crossref_primary_10_1007_s10067_014_2626_y
crossref_primary_10_1186_s13075_021_02474_2
crossref_primary_10_1136_annrheumdis_2013_204229
crossref_primary_10_1016_j_ad_2013_10_020
crossref_primary_10_1186_s41927_022_00298_4
crossref_primary_10_1055_a_1059_9475
crossref_primary_10_1016_j_rhum_2017_03_016
crossref_primary_10_1007_s11926_014_0418_7
crossref_primary_10_1093_rheumatology_keaa030
crossref_primary_10_1093_rheumatology_keaa271
crossref_primary_10_3390_diagnostics10110944
crossref_primary_10_1016_S0140_6736_15_00347_5
crossref_primary_10_1186_s13063_021_05142_7
crossref_primary_10_3899_jrheum_160386
crossref_primary_10_4236_ojra_2017_71005
crossref_primary_10_3892_etm_2023_11962
crossref_primary_10_1016_j_reuma_2018_09_008
crossref_primary_10_1002_acr2_11537
crossref_primary_10_1007_s12016_017_8630_7
crossref_primary_10_3899_jrheum_210010
crossref_primary_10_3390_diagnostics13203250
crossref_primary_10_1016_j_jaut_2016_10_009
crossref_primary_10_1016_j_reuma_2017_08_007
crossref_primary_10_1002_acr_22204
crossref_primary_10_1080_00325481_2016_1220809
crossref_primary_10_1093_rheumatology_kez237
crossref_primary_10_1007_s10067_015_2886_1
crossref_primary_10_1186_s12891_016_1292_4
crossref_primary_10_3899_jrheum_150805
crossref_primary_10_1007_s40266_015_0280_y
crossref_primary_10_1177_1759720X241283536
crossref_primary_10_1111_1756_185X_12744
crossref_primary_10_1517_21678707_2014_917952
crossref_primary_10_1016_j_adengl_2013_10_013
crossref_primary_10_3390_jpm13071153
crossref_primary_10_1016_j_rdc_2015_07_009
crossref_primary_10_1186_s13075_014_0476_2
crossref_primary_10_1093_rheumatology_keaa028
crossref_primary_10_1111_jdv_12222
crossref_primary_10_1093_rheumatology_keaa025
crossref_primary_10_3899_jrheum_160120
crossref_primary_10_1016_j_monrhu_2020_05_001
crossref_primary_10_1136_annrheumdis_2017_211137
crossref_primary_10_1002_art_39700
crossref_primary_10_1136_rmdopen_2022_002626
crossref_primary_10_3899_jrheum_201317
crossref_primary_10_3899_jrheum_161459
crossref_primary_10_1007_s10067_024_06991_8
crossref_primary_10_1186_s13075_018_1739_0
crossref_primary_10_1016_j_berh_2021_101680
crossref_primary_10_3899_jrheum_160924
crossref_primary_10_1007_s11926_015_0509_0
crossref_primary_10_1007_s11926_017_0633_0
crossref_primary_10_1016_j_ejr_2023_10_001
crossref_primary_10_1136_bmjopen_2015_010650
crossref_primary_10_1111_bjd_12748
crossref_primary_10_3899_jrheum_151404
crossref_primary_10_3899_jrheum_131250
crossref_primary_10_3899_jrheum_141156
crossref_primary_10_1093_rheumatology_keab338
crossref_primary_10_1136_rmdopen_2022_002972
crossref_primary_10_3899_jrheum_2023_0177
crossref_primary_10_1016_j_berh_2018_09_006
crossref_primary_10_1136_annrheumdis_2015_208509
crossref_primary_10_1093_rheumatology_kev009
crossref_primary_10_1038_s41584_018_0147_9
crossref_primary_10_3899_jrheum_2024_0230
crossref_primary_10_1016_j_injr_2013_11_007
crossref_primary_10_1002_acr_23345
crossref_primary_10_1016_j_berh_2021_101669
crossref_primary_10_1016_j_berh_2014_10_004
crossref_primary_10_1002_acr_23460
crossref_primary_10_1016_j_autrev_2015_05_010
crossref_primary_10_46833_reumatologiasp_2020_19_4_21_24
crossref_primary_10_1136_annrheumdis_2015_208617
crossref_primary_10_1186_s13075_020_02254_4
crossref_primary_10_3389_fimmu_2021_614653
crossref_primary_10_1016_j_semarthrit_2017_10_021
crossref_primary_10_1007_s10067_015_3053_4
crossref_primary_10_1007_s40744_017_0053_7
crossref_primary_10_1002_acr_23571
crossref_primary_10_1586_1744666X_2015_1009897
crossref_primary_10_4103_injr_injr_296_20
crossref_primary_10_1136_annrheumdis_2018_214140
crossref_primary_10_1097_JD9_0000000000000300
crossref_primary_10_3390_diagnostics11040669
crossref_primary_10_1136_rmdopen_2022_002195
crossref_primary_10_1515_acm_2016_0015
crossref_primary_10_1097_BOR_0000000000001089
crossref_primary_10_1002_art_40851
crossref_primary_10_1093_rheumatology_kez305
crossref_primary_10_1016_j_rdc_2016_01_002
crossref_primary_10_1002_acr2_11714
crossref_primary_10_3899_jrheum_210075
crossref_primary_10_1177_1759720X241240913
crossref_primary_10_1136_annrheumdis_2014_205207
crossref_primary_10_1136_annrheumdis_2015_207507
crossref_primary_10_3899_jrheum_220547
crossref_primary_10_3899_jrheum_130462
crossref_primary_10_1007_s10067_017_3953_6
crossref_primary_10_1007_s40265_014_0191_y
crossref_primary_10_1007_s40674_017_0067_x
crossref_primary_10_1016_j_berh_2018_12_002
crossref_primary_10_1016_j_semarthrit_2016_05_010
crossref_primary_10_3899_jrheum_2023_0530
crossref_primary_10_1586_1744666X_2016_1147954
crossref_primary_10_1186_s41927_022_00279_7
crossref_primary_10_1016_j_reumae_2018_09_012
crossref_primary_10_1080_13696998_2017_1384737
crossref_primary_10_1136_annrheumdis_2013_203419
crossref_primary_10_1007_s40744_024_00690_1
crossref_primary_10_3899_jrheum_170932
crossref_primary_10_3899_jrheum_2024_0152
crossref_primary_10_1080_1744666X_2024_2384705
crossref_primary_10_1016_j_jbspin_2015_06_018
crossref_primary_10_1093_rheumatology_kew375
crossref_primary_10_1093_rheumatology_kex344
crossref_primary_10_1038_s41584_025_01229_6
crossref_primary_10_1080_1744666X_2018_1429918
crossref_primary_10_1136_annrheumdis_2021_220562
crossref_primary_10_1007_s40744_019_0159_1
crossref_primary_10_1186_s13075_018_1773_y
crossref_primary_10_1155_2012_839425
crossref_primary_10_1111_1756_185X_13441
crossref_primary_10_2217_ijr_13_69
crossref_primary_10_25259_IJDVL_29_2023
crossref_primary_10_1002_art_40391
crossref_primary_10_1002_acr_22844
crossref_primary_10_3899_jrheum_181472
crossref_primary_10_3390_ijms242015299
crossref_primary_10_1080_13543784_2024_2383421
crossref_primary_10_3390_biomedicines10123193
crossref_primary_10_1002_acr_23930
crossref_primary_10_1007_s10067_017_3769_4
crossref_primary_10_1007_s11306_023_02079_7
crossref_primary_10_1136_rmdopen_2023_003548
crossref_primary_10_1136_annrheumdis_2015_208806
crossref_primary_10_1007_s40265_014_0246_0
crossref_primary_10_3899_jrheum_170112
crossref_primary_10_1007_s40744_024_00708_8
crossref_primary_10_3899_jrheum_140172
crossref_primary_10_3899_jrheum_140171
crossref_primary_10_1093_rheumatology_key417
crossref_primary_10_3899_jrheum_190867
Cites_doi 10.1136/annrheumdis-2011-200093
10.1002/art.23568
10.1136/ard.62.1.20
10.1093/rheumatology/39.2.148
10.3899/jrheum.100857
10.1136/ard.2003.006296
10.1093/rheumatology/35.11.1101
10.1136/ard.2004.032268
10.1136/ard.2009.117945
10.1002/art.1780230202
10.3899/jrheum.101116
10.1002/art.1780390105
10.1159/000250839
10.1136/ard.62.2.127
10.1136/ard.2010.129379
10.1002/art.1780391210
10.1016/S0140-6736(00)02530-7
10.1136/ard.2007.084244
10.1002/art.24562
10.1136/ard.2008.102053
10.1136/ard.2008.094870
10.1080/03610920802527080
10.1136/bmj.306.6890.1429
10.1016/S1085-5629(98)80026-6
ContentType Journal Article
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Copyright: 2013 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
– notice: Copyright: 2013 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1136/annrheumdis-2012-201341
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
BMJ Journals
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

ProQuest Central Student
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 991
ExternalDocumentID 4008598591
22798567
10_1136_annrheumdis_2012_201341
ark_67375_NVC_MQXHKFB3_2
annrheumdis
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United Kingdom--UK
GeographicLocations_xml – name: United Kingdom--UK
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
0R~
3V.
BSCLL
FRP
IGG
RHF
AAFWJ
AALRI
AAYXX
CITATION
PHGZM
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-b422t-ae971663b4f4f3d2d1850005c78b4165a883eca7e29122bb6d96216f74796df43
IEDL.DBID 7X7
ISSN 0003-4967
1468-2060
IngestDate Fri Sep 05 13:41:36 EDT 2025
Fri Jul 25 10:47:43 EDT 2025
Sat Feb 15 01:21:14 EST 2025
Tue Jul 01 04:23:27 EDT 2025
Thu Apr 24 22:54:46 EDT 2025
Wed Oct 30 09:36:48 EDT 2024
Thu Apr 24 23:01:50 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b422t-ae971663b4f4f3d2d1850005c78b4165a883eca7e29122bb6d96216f74796df43
Notes istex:CFC9AF95FD2FE305E9B4EB083B11D70D3216749C
ArticleID:annrheumdis-2012-201341
ark:/67375/NVC-MQXHKFB3-2
local:annrheumdis;72/6/986
href:annrheumdis-72-986.pdf
PMID:22798567
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 22798567
PQID 1777885079
PQPubID 2041045
PageCount 6
ParticipantIDs proquest_miscellaneous_1350891843
proquest_journals_1777885079
pubmed_primary_22798567
crossref_citationtrail_10_1136_annrheumdis_2012_201341
crossref_primary_10_1136_annrheumdis_2012_201341
istex_primary_ark_67375_NVC_MQXHKFB3_2
bmj_primary_10_1136_annrheumdis_2012_201341
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20130600
2013-06
2013-06-00
2013-Jun
20130601
PublicationDateYYYYMMDD 2013-06-01
PublicationDate_xml – month: 06
  year: 2013
  text: 20130600
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Kidlington
PublicationTitle Annals of the rheumatic diseases
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2013
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
Elsevier Limited
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: Elsevier Limited
References Heuft-Dorenbosch, Spoorenberg, van Tubergen 2003; 62
Healy, Helliwell 2008; 59
van Gestel, Prevoo, Van't Hof 1996; 39
Nell-Duxneuner, Stamm, Machold 2010; 69
Boers, Brooks, Strand 1998; 25
Cauli, Gladman, Mathieu 2011; 38
Lukas, Landewe, Sieper 2009; 68
Eberl, Studnicka-Benke, Hitzelhammer 2000; 39
Ware 1993; 306
Antoni, Krueger, de Vlam 2005; 64
Cassell, Bieber, Rich 2007; 34
Clegg, Reda, Mejias 1996; 39
Jenkinson, Mallorie, Whitelock 1994; 21
Helliwell, Fitzgerald, Strand 2011; 38
Fransen, Kavanaugh, Borm 2009; 38
Fries, Spitz, Kraines 1980; 23
Finlay 1998; 17
Chandran, Gottlieb, Cook 2009; 61
Coates, Fransen, Helliwell 2010; 69
Gladman, Mease, Strand 2007; 34
Fredricksson, Pettersson 1978; 157
Doward, Spoorenberg, Cook 2003; 62
FitzGerald, Helliwell, Mease 2012; 71
Mumtaz, Gallagher, Kirby 2011; 70
McKenna, Doward, Whalley 2004; 63
Maksymowych, Mallon, Morrow 2009; 68
Mease, Goffe, Metz 2000; 356
Prevoo, van Gestel, van t'Hof 1996; 35
Fredricksson (10.1136/annrheumdis-2012-201341_bib16) 1978; 157
Finlay (10.1136/annrheumdis-2012-201341_bib21) 1998; 17
Antoni (10.1136/annrheumdis-2012-201341_bib2) 2005; 64
FitzGerald (10.1136/annrheumdis-2012-201341_bib8) 2012; 71
Prevoo (10.1136/annrheumdis-2012-201341_bib9) 1996; 35
Cauli (10.1136/annrheumdis-2012-201341_bib28) 2011; 38
Fries (10.1136/annrheumdis-2012-201341_bib25) 1980; 23
Fransen (10.1136/annrheumdis-2012-201341_bib13) 2009; 38
Jenkinson (10.1136/annrheumdis-2012-201341_bib15) 1994; 21
Coates (10.1136/annrheumdis-2012-201341_bib14) 2010; 69
Maksymowych (10.1136/annrheumdis-2012-201341_bib20) 2009; 68
Boers (10.1136/annrheumdis-2012-201341_bib27) 1998; 25
Clegg (10.1136/annrheumdis-2012-201341_bib1) 1996; 39
Heuft-Dorenbosch (10.1136/annrheumdis-2012-201341_bib18) 2003; 62
van Gestel (10.1136/annrheumdis-2012-201341_bib10) 1996; 39
Gladman (10.1136/annrheumdis-2012-201341_bib11) 2007; 34
Nell-Duxneuner (10.1136/annrheumdis-2012-201341_bib7) 2010; 69
Cassell (10.1136/annrheumdis-2012-201341_bib17) 2007; 34
Doward (10.1136/annrheumdis-2012-201341_bib22) 2003; 62
Chandran (10.1136/annrheumdis-2012-201341_bib26) 2009; 61
Eberl (10.1136/annrheumdis-2012-201341_bib6) 2000; 39
Helliwell (10.1136/annrheumdis-2012-201341_bib5) 2011; 38
Ware (10.1136/annrheumdis-2012-201341_bib24) 1993; 306
Healy (10.1136/annrheumdis-2012-201341_bib19) 2008; 59
McKenna (10.1136/annrheumdis-2012-201341_bib23) 2004; 63
Mease (10.1136/annrheumdis-2012-201341_bib3) 2000; 356
Lukas (10.1136/annrheumdis-2012-201341_bib12) 2009; 68
Mumtaz (10.1136/annrheumdis-2012-201341_bib4) 2011; 70
References_xml – volume: 25
  start-page: 198
  year: 1998
  article-title: The OMERACT filter for Outcome Measures in Rheumatology
  publication-title: J Rheumatol
– volume: 63
  start-page: 162
  year: 2004
  article-title: Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
  publication-title: Ann Rheum Dis
– volume: 68
  start-page: 948
  year: 2009
  article-title: Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis index
  publication-title: Ann Rheum Dis
– volume: 61
  start-page: 1235
  year: 2009
  article-title: International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis
  publication-title: Arthr Rheum
– volume: 70
  start-page: 272
  year: 2011
  article-title: Development of a preliminary composite disease activity index in psoriatic arthritis
  publication-title: Ann Rheum Dis
– volume: 34
  start-page: 1167
  year: 2007
  article-title: Consensus on a core set of domains for psoriatic arthritis
  publication-title: J Rheumatol
– volume: 39
  start-page: 148
  year: 2000
  article-title: Development of a disease activity index for the assessment of reactive arthritis (DAREA)
  publication-title: Rheumatology
– volume: 38
  start-page: 3461
  year: 2009
  article-title: Desirability scores for assessing multiple outcomes in systemic rheumatic diseases
  publication-title: Commun Stat Theory Methods
– volume: 356
  start-page: 385
  year: 2000
  article-title: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]
  publication-title: Lancet
– volume: 69
  start-page: 48
  year: 2010
  article-title: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
  publication-title: Ann Rheum Dis
– volume: 62
  start-page: 127
  year: 2003
  article-title: Assessment of enthesitis in ankylosing spondylitis
  publication-title: Ann Rheum Dis
– volume: 38
  start-page: 898
  year: 2011
  article-title: Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study
  publication-title: J Rheumatol
– volume: 157
  start-page: 238
  year: 1978
  article-title: Severe psoriasis–oral therapy with a new retinoid
  publication-title: Dermatologica
– volume: 23
  start-page: 137
  year: 1980
  article-title: Measurement of patient outcome in arthritis
  publication-title: Arthr Rheum
– volume: 39
  start-page: 2013
  year: 1996
  article-title: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study
  publication-title: Arthr Rheum
– volume: 62
  start-page: 20
  year: 2003
  article-title: Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
  publication-title: Ann Rheum Dis
– volume: 71
  start-page: 358
  year: 2012
  article-title: Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set
  publication-title: Ann Rheum Dis
– volume: 35
  start-page: 1101
  year: 1996
  article-title: Remission in a proposed study of patients with rheumatoid arthritis. American Rheumatism Association preliminary criteria in relation to the disease activity score
  publication-title: Rheumatology
– volume: 38
  start-page: 540
  year: 2011
  article-title: Composite measures in psoriatic arthritis. Report from the GRAPPA 2009 annual meeting
  publication-title: J Rheumatol
– volume: 17
  start-page: 291
  year: 1998
  article-title: Quality of life assessments in dermatology
  publication-title: Semin Cutan Med Surg
– volume: 21
  start-page: 1694
  year: 1994
  article-title: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index
  publication-title: J Rheumatol
– volume: 64
  start-page: 1150
  year: 2005
  article-title: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
  publication-title: Ann Rheum Dis
– volume: 69
  start-page: 546
  year: 2010
  article-title: Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
  publication-title: Ann Rheum Dis
– volume: 34
  start-page: 123
  year: 2007
  article-title: The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis
  publication-title: J Rheumatol
– volume: 306
  start-page: 1429
  year: 1993
  article-title: Measuring patients’ views: the optimum outcome measure
  publication-title: BMJ
– volume: 68
  start-page: 18
  year: 2009
  article-title: Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
  publication-title: Ann Rheum Dis
– volume: 59
  start-page: 686
  year: 2008
  article-title: Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific for psoriatic arthritis
  publication-title: Arthr Care Res
– volume: 39
  start-page: 34
  year: 1996
  article-title: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria
  publication-title: Arthr Rheum
– volume: 71
  start-page: 358
  year: 2012
  ident: 10.1136/annrheumdis-2012-201341_bib8
  article-title: Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200093
– volume: 59
  start-page: 686
  year: 2008
  ident: 10.1136/annrheumdis-2012-201341_bib19
  article-title: Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific for psoriatic arthritis
  publication-title: Arthr Care Res
  doi: 10.1002/art.23568
– volume: 62
  start-page: 20
  year: 2003
  ident: 10.1136/annrheumdis-2012-201341_bib22
  article-title: Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.62.1.20
– volume: 39
  start-page: 148
  year: 2000
  ident: 10.1136/annrheumdis-2012-201341_bib6
  article-title: Development of a disease activity index for the assessment of reactive arthritis (DAREA)
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/39.2.148
– volume: 38
  start-page: 898
  year: 2011
  ident: 10.1136/annrheumdis-2012-201341_bib28
  article-title: Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.100857
– volume: 25
  start-page: 198
  year: 1998
  ident: 10.1136/annrheumdis-2012-201341_bib27
  article-title: The OMERACT filter for Outcome Measures in Rheumatology
  publication-title: J Rheumatol
– volume: 21
  start-page: 1694
  year: 1994
  ident: 10.1136/annrheumdis-2012-201341_bib15
  article-title: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index
  publication-title: J Rheumatol
– volume: 63
  start-page: 162
  year: 2004
  ident: 10.1136/annrheumdis-2012-201341_bib23
  article-title: Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2003.006296
– volume: 35
  start-page: 1101
  year: 1996
  ident: 10.1136/annrheumdis-2012-201341_bib9
  article-title: Remission in a proposed study of patients with rheumatoid arthritis. American Rheumatism Association preliminary criteria in relation to the disease activity score
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/35.11.1101
– volume: 34
  start-page: 1167
  year: 2007
  ident: 10.1136/annrheumdis-2012-201341_bib11
  article-title: Consensus on a core set of domains for psoriatic arthritis
  publication-title: J Rheumatol
– volume: 64
  start-page: 1150
  year: 2005
  ident: 10.1136/annrheumdis-2012-201341_bib2
  article-title: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2004.032268
– volume: 69
  start-page: 546
  year: 2010
  ident: 10.1136/annrheumdis-2012-201341_bib7
  article-title: Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2009.117945
– volume: 23
  start-page: 137
  year: 1980
  ident: 10.1136/annrheumdis-2012-201341_bib25
  article-title: Measurement of patient outcome in arthritis
  publication-title: Arthr Rheum
  doi: 10.1002/art.1780230202
– volume: 38
  start-page: 540
  year: 2011
  ident: 10.1136/annrheumdis-2012-201341_bib5
  article-title: Composite measures in psoriatic arthritis. Report from the GRAPPA 2009 annual meeting
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.101116
– volume: 39
  start-page: 34
  year: 1996
  ident: 10.1136/annrheumdis-2012-201341_bib10
  publication-title: Arthr Rheum
  doi: 10.1002/art.1780390105
– volume: 157
  start-page: 238
  year: 1978
  ident: 10.1136/annrheumdis-2012-201341_bib16
  article-title: Severe psoriasis–oral therapy with a new retinoid
  publication-title: Dermatologica
  doi: 10.1159/000250839
– volume: 62
  start-page: 127
  year: 2003
  ident: 10.1136/annrheumdis-2012-201341_bib18
  article-title: Assessment of enthesitis in ankylosing spondylitis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.62.2.127
– volume: 70
  start-page: 272
  year: 2011
  ident: 10.1136/annrheumdis-2012-201341_bib4
  article-title: Development of a preliminary composite disease activity index in psoriatic arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.129379
– volume: 39
  start-page: 2013
  year: 1996
  ident: 10.1136/annrheumdis-2012-201341_bib1
  article-title: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study
  publication-title: Arthr Rheum
  doi: 10.1002/art.1780391210
– volume: 356
  start-page: 385
  year: 2000
  ident: 10.1136/annrheumdis-2012-201341_bib3
  article-title: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]
  publication-title: Lancet
  doi: 10.1016/S0140-6736(00)02530-7
– volume: 68
  start-page: 948
  year: 2009
  ident: 10.1136/annrheumdis-2012-201341_bib20
  article-title: Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis index
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2007.084244
– volume: 61
  start-page: 1235
  year: 2009
  ident: 10.1136/annrheumdis-2012-201341_bib26
  article-title: International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis
  publication-title: Arthr Rheum
  doi: 10.1002/art.24562
– volume: 69
  start-page: 48
  year: 2010
  ident: 10.1136/annrheumdis-2012-201341_bib14
  article-title: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.102053
– volume: 34
  start-page: 123
  year: 2007
  ident: 10.1136/annrheumdis-2012-201341_bib17
  article-title: The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis
  publication-title: J Rheumatol
– volume: 68
  start-page: 18
  year: 2009
  ident: 10.1136/annrheumdis-2012-201341_bib12
  article-title: Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.094870
– volume: 38
  start-page: 3461
  year: 2009
  ident: 10.1136/annrheumdis-2012-201341_bib13
  article-title: Desirability scores for assessing multiple outcomes in systemic rheumatic diseases
  publication-title: Commun Stat Theory Methods
  doi: 10.1080/03610920802527080
– volume: 306
  start-page: 1429
  year: 1993
  ident: 10.1136/annrheumdis-2012-201341_bib24
  article-title: Measuring patients' views: the optimum outcome measure
  publication-title: BMJ
  doi: 10.1136/bmj.306.6890.1429
– volume: 17
  start-page: 291
  year: 1998
  ident: 10.1136/annrheumdis-2012-201341_bib21
  article-title: Quality of life assessments in dermatology
  publication-title: Semin Cutan Med Surg
  doi: 10.1016/S1085-5629(98)80026-6
SSID ssj0000818
Score 2.5395155
Snippet Objective To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods Data from routine clinic visits at multiple centres were...
To develop new composite disease activity indices for psoriatic arthritis (PsA). Data from routine clinic visits at multiple centres were collected in a...
To develop new composite disease activity indices for psoriatic arthritis (PsA).OBJECTIVETo develop new composite disease activity indices for psoriatic...
SourceID proquest
pubmed
crossref
istex
bmj
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 986
SubjectTerms Adult
Arthritis
Arthritis, Psoriatic - diagnosis
Bowel disease
Colleges & universities
Dermatology
Female
Humans
Linear Models
Male
Middle Aged
Psoriasis
Quality
Rheumatic diseases
Rheumatology
ROC Curve
Severity of Illness Index
Skin
Teaching hospitals
Title The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
URI http://ard.bmj.com/content/72/6/986.full
https://api.istex.fr/ark:/67375/NVC-MQXHKFB3-2/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/22798567
https://www.proquest.com/docview/1777885079
https://www.proquest.com/docview/1350891843
Volume 72
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bixMxFA7uFsSXxbuj6xJBRJHBJpNJMk-yW1qL0qKLK30Lkxur7rZ12oI_33Nm0hYfvLzMyyQzkHNy8p2cy0fI80qXMUYpcm9tmYuqH3LbZy6PpVfCO8F0xOLkyVSOL8T7WTlLF26rlFa5tYmtofYLh3fkb5hS4K0BeqneLn_kyBqF0dVEoXFAegyQCFI3qJnaW2LN9JYxT1RSpfwuVrQkL81l2Fz7rytQFMbxUSAt_IG9_vbbGdXD5f75ZwDaHkSj2-QoIUh62on8DrkR5nfJzUmKkd8jG5A89ftcILqI1GHxCvr2FFPIMU8LhnShGYqVDUggQWEMbdqUWR8airFssCEUQC1drmAlsLUrBUW7bNsg0Zfvzk8HQ5pucl7dJxej4efBOE_kCrkVnK_zOmDzKFlYEUUsPPdwcCOAc0pbAGllrXURXK0Crxjn1kpfSc5kBPejkj6K4gE5nC_m4RGhug4xRO1t7Sx4e7J2YLWcAkeIl7VVMSOvYVHNsmufYVq3o2hLobciMCgC04kgI3K7-MalPuVIl3H174n93cT__teLVrq78XXzHTPdVGmmXwZm8mk2_jA6KwzPyPFW_CZt8pXZq2RGnu1ew_bEmEs9D4sNjCkAAVdIqpORh53a7H6GzRt1KdXjv3_8CbnFOw6OvM-OyeG62YSngITW9qRV9xPSOxtOP57_Aq4jCJE
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwEB7tthJwQbwJLGAkQCAU0TiOkxxWaLe0dOm2gtUu6s3Esa3lsW1JWwF_jt_GTB6tOPC47CWXOLbkmYy_8Tw-gEdpEjnnpPCN1pEv0o71dSfIfReZWJhcBImj4uTRWA5OxJtJNNmCn00tDKVVNjaxNNRmltMd-YsgjtFbQ_SSvpx_9Yk1iqKrDYVGVlMrmN2yxVhd2DG0P76hC7fYPXiF8n7Meb933B34NcuArwXnSz-z1EVJhlo44ULDDZ5ghGTyONGIVqIsSUKbZ7HlacC51tKkkgfSIQ5PpXEixHm3oS3oAqUF7f3e-O3R5ixIgqTh7BOpjOsMsyAsaWaKU7s6Mx8XqKoBp0dIxPTb-uzTb6dkmwT-_c8QuDwK-1fgco1h2V6ldFdhy06vwYVRHaW_DivUPWY22Uhs5lhO5TN0u8AoiZ0yxXBIFRxiVFtBFBYMx7CiTNo1tmAUTUcrxhBWs_kCZUHNZRmq-mnZiIk9fX201-2x-i7p2Q04OZeNvwmt6WxqbwNLMuusS4zOco3-psxytJt5jK4YjzIdOw-e46aqedXAQ5WOT1gWYzciUCQCVYnAA9lsvsrrTulE2PHl3x921h_-91pPSumux2fFZ8q1iyM1ft9Vo3eTwbC_HyruwU4jflWbmYXa_BQePFy_RgNBUZ9samcrHBMiBk-J1seDW5XarBej9pFJJOM7f5_8AVwcHI8O1eHBeHgXLvGKEcTvBDvQWhYrew9x2VLfr5WfwYfz_t9-AaExSM0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa2VZp4QdwJDDASIBCK1jiJnTxMaOtaOkqrMbGpb8aObY3L2pK2Av4iv4pzEqcVD1xe9tKXOonkc3zOd3wuHyFP8ix1zvEkNFqnYZK3bajbURG61IjEFEmUOWxOHo54_zR5M07HG-Rn0wuDZZWNTawMtZkWeEe-GwkB0Rqgl3zX-bKI48Peq9nXEBmkMNPa0GkoT7Ng9qpxY77JY2B_fINwbr53dAiyf8pYr_u-0w8940CoE8YWobI4UYnHOnGJiw0z4M0Q1RQi04BcUpVlsS2UsCyPGNOam5yziDvA5Dk3LonhvZukJcDrQyDYOuiOjk_WfiGLsoa_L8m58NVmUVxRzpTndnlhPs5BbSOGPzGS1G_qi0-_ecwWCv_7n-Fw5RZ718hVj2fpfq2A18mGndwg20Ofsb9JlqCH1Kwrk-jU0QJbafCmgWJBO1aNwZI6UUSxzwLpLCisoWVVwGtsSTGzDhaNAsSmsznIAgfNUlD782ooE33--mS_06X-XunFLXJ6KRt_m2xNphN7l9BMWWddZrQqNMSeXBVgQwsBYRlLlRYuIC9hU-WsHuYhqyAorhqzGxFIFIGsRRAQ3my-LPzUdCTv-PLvB9urB__7W88q6a7Wq_Iz1t2JVI7OOnL4btwf9A5iyQKy04hfepMzl-sDEpDHq7_BWGAGSE3sdAlrYsDjOVL8BOROrTarj-EoySzl4t7fX_6IbMO5k2-PRoP75AqryUHCdrRDthbl0j4AiLbQD73uU_Lhso_bLz5PTRE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+development+of+candidate+composite+disease+activity+and+responder+indices+for+psoriatic+arthritis+%28GRACE+project%29&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Helliwell%2C+Philip+S&rft.au=FitzGerald%2C+Oliver&rft.au=Fransen%2C+Jaap&rft.au=Gladman%2C+Dafna+D&rft.date=2013-06-01&rft.issn=1468-2060&rft.eissn=1468-2060&rft.volume=72&rft.issue=6&rft.spage=986&rft_id=info:doi/10.1136%2Fannrheumdis-2012-201341&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon